Myocardial infarction and atrial fibrillation: Different impact of anti-IIa vs anti-Xa new oral anticoagulants: A meta-analysis of the interventional trials

International Journal of Cardiology

Volumn 178, Issue , 2015, Pages 8-9

  Loffredo, Lorenzo ^a   Perri, Ludovica ^a   Violi, Francesco ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Atrial fibrillation; Myocardial infarction; New oral anticoagulants

Indexed keywords

ACENOCOUMAROL; ANTIVITAMIN K; APIXABAN; DABIGATRAN; EDOXABAN; RIVAROXABAN; WARFARIN; XIMELAGATRAN; ANTICOAGULANTS;

ACUTE CORONARY SYNDROME; ARTICLE; COMORBIDITY; CORONARY RISK; DEEP VEIN THROMBOSIS; FOLLOW UP; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HUMAN; META ANALYSIS (TOPIC); MORBIDITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; ADMINISTRATION, ORAL; ATRIAL FIBRILLATION; COMPARATIVE STUDY; DOUBLE-BLIND METHOD; HUMANS; META ANALYSIS; METHODS; MYOCARDIAL INFARCTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ANTICOAGULANTS; ATRIAL FIBRILLATION; DOUBLE-BLIND METHOD; HUMANS; MYOCARDIAL INFARCTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME; WARFARIN;

EID: 84916241835     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2014.10.124     Document Type: Article

References (10)

1. F. Violi, and L. Loffredo Thromboembolism or atherothromboembolism in atrial fibrillation? Circ. Arrhythm. Electrophysiol. 5 2012 1053 1055
2. H. Mani, and E. Lindhoff-Last New oral anticoagulants in patients with nonvalvular atrial fibrillation: a review of pharmacokinetics, safety, efficacy, quality of life, and cost effectiveness Drug Des. Dev. Ther. 8 2014 789 798
3. C.T. Ruff, R.P. Giugliano, E. Braunwald, E.B. Hoffman, N. Deenadayalu, and M.D. Ezekowitz Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials Lancet 383 2014 955 962
4. R. Artang, E. Rome, J.D. Nielsen, and H.J. Vidaillet Meta-analysis of randomized controlled trials on risk of myocardial infarction from the use of oral direct thrombin inhibitors Am. J. Cardiol. 112 2013 1973 1979
5. K. Uchino, and A.V. Hernandez Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials Arch. Intern. Med. 172 2012 397 402
6. J. Douxfils, F. Buckinx, F. Mullier, V. Minet, V. Rabenda, and J.Y. Reginster Dabigatran etexilate and risk of myocardial infarction, other cardiovascular events, major bleeding, and all-cause mortality: a systematic review and meta-analysis of randomized controlled trials J. Am. Heart Assoc. 3 2014 e000515
7. J.H. Griffin Blood coagulation. The thrombin paradox Nature 378 1995 337 338
8. J.G. Schneider, B. Isermann, M.E. Kleber, H. Wang, B.O. Boehm, and T.B. Grammer Inverse association of the endogenous thrombin potential (ETP) with cardiovascular death: the Ludwigshafen Risk and Cardiovascular Health (LURIC) study Int. J. Cardiol. 176 2014 139 144
9. D. Ardissino, P.A. Merlini, K.A. Bauer, M. Galvani, F. Ottani, and F. Franchi Coagulation activation and long-term outcome in acute coronary syndromes Blood 102 2003 2731 2735
10. P. Theroux, F. Perez-Villa, D. Waters, J. Lesperance, F. Shabani, and R. Bonan Randomized double-blind comparison of two doses of Hirulog with heparin as adjunctive therapy to streptokinase to promote early patency of the infarct-related artery in acute myocardial infarction Circulation 91 1995 2132 2139